Estudio de alteraciones autoinmunes en pacientes con SMD.

Annal of Hematology

Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.

Caballero JC1, Sánchez Barba M2, Hernández Sánchez JM3, Such E4, Janusz K3, Sanz G4, Cabrero M1, Chillón C5, Cervera J4, Hurtado AM6, Jerez A6, Calderón Cabrera C7, Valcárcel D8, Lumbreras E3, Abáigar M3, López Cadenas F1, Hernández Rivas JM1,3, Del Cañizo MC1,9, Díez Campelo M10,11.Ann Hematol. 2019 Sep;98(9):2151-2162. doi: 10.1007/s00277-019-03751-6. Epub 2019 Jul 16

Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology.

Bastida JM, López-Godino O, Vicente-Sánchez A, Bonanad-Boix S, Xicoy-Cirici B, Hernández-Sánchez JM, Such E, Cervera J, Caballero-Berrocal JC, López-Cadenas F, Arnao-Herráiz M, Rodríguez I, Llopis-Calatayud I, Jiménez MJ, Del Cañizo-Roldán MC, Díez-Campelo M.Int J Lab Hematol. 2019 Feb;41(1):109-117. doi: 10.1111/ijlh.12933. Epub 2018 Oct 5. PMID: 30290085

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Palomo L1, Ibáñez M2,3,4, Abáigar M5, Vázquez I6,7, Álvarez S8, Cabezón M9, Tazón-Vega B10,11, Rapado I12,13,14, Fuster-Tormo F1, Cervera J2,3,15, Benito R5, Larrayoz MJ6,7, Cigudosa JC8, Zamora L9, Valcárcel D10,11, Cedena MT12,13,14, Acha P1, Hernández-Sánchez JM5,16, Fernández-Mercado M6,17,18, Sanz G2,3, Hernández-Rivas JM5,16,19, Calasanz MJ6,7, Solé F1, Such E2,3,4; Spanish Group of MDS (GESMD).AID – BJH16175. Manuscript ID – BJH-2019-00857.R1.Br J Haematol. 2020 Mar;188(5):605-622. doi: 10.1111/bjh.16175. Epub 2019 Oct 16.

Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.

Montes P, Bernal M, Campo L.N, González Ramírez A.R, Jiménez P, Garrido P, Jurado M, Garrido F, Ruiz-Cabello F, Hernández, F.Cancer Immunol Immunother. 2019 Dec;68(12):2015-2027. doi: 10.1007/s00262-019-02420-x. Epub 2019 Nov 8.

The importance of adequate recognition of normal and dysplastic myelopoiesis for the diagnosis of myelodysplastic syndromes.

Lourdes Florensa*, Leonor Arenillas*, Xavier Calvo*, Encarnación Pérez-Vila, Sara Montesdeoca, Ana Ferrer and Soledad Woessner, Escola de Citologia Hematològica Soledad Woessner-Parc de Salut Mar, Laboratorio de Citología Hematológica, Patología, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain *contributed equally to this work. Histol Histopathol (2019) 34: 857-873

Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.Paola Montes, Martin Kerick, Mónica Bernal, Francisca Hernández.

Oncotarget. 2018; 9:36929-36944